Omar Nadeem

New Capabilities

Presented ImmunoPRISM results at the EHA Congress, June 2026

Doctors at Dana-Farber Cancer Institute gave teclistamab, a bispecific antibody already approved for advanced myeloma, to 45 patients with high-risk smoldering multiple myeloma. Complete remission followed in 77.8% of them.

Updated 2 hours ago